Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc. (ORMP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Oramed is a pharmaceutical company developing oral delivery solutions for therapeutic proteins, primarily focusing on oral insulin (ORMD-0801). Following a failed Phase 3 trial in 2023, the company shifted strategy to evaluate subpopulations and pursue strategic alternatives. In 2025, the company significantly diversified its capital allocation into strategic investments in healthcare companies (Alpha Tau, Lifeward, Scilex) and real estate projects.
Key Financial Metrics
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Revenues | $2,000 | $0 |
| Net Income (Loss) | $64,016 | $(19,103) |
| Diluted EPS | $1.50 | $(0.48) |
| Research & Development Expenses | $(6,381) | $(6,324) |
| General & Administrative Expenses | $(8,720) | $(6,457) |
| Financial Income (Net) | $89,454 | $(2,286) |
| Cash and Cash Equivalents (Year End) | $45,947 | $54,420 |
| Working Capital | $114,185 | $137,536 |
| Total Assets | $230,864 | $155,278 |
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $64.0 million in 2025, a reversal from a $19.1 million net loss in 2024. This turnaround was driven almost entirely by non-operating financial income rather than core pharmaceutical operations.
- Financial Income Surge: Net financial income jumped to $89.5 million (from $2.3 million expense) due to significant unrealized gains on investments, specifically the revaluation of the Alpha Tau investment ($37.0 million gain) and Scilex notes ($44.6 million gain).
- Revenue Recognition: The company recognized $2.0 million in revenue related to the HTIT License Agreement following a waiver of claims, whereas 2024 had zero revenue.
- Expense Growth: General and Administrative expenses increased 35% to $8.7 million, primarily due to higher stock-based compensation and professional fees.
- Investment Portfolio: The company significantly expanded its investment portfolio, acquiring a ~17% stake in Alpha Tau Medical Ltd. and entering into complex debt/equity arrangements with Scilex and Lifeward.
Guidance, Outlook, and Strategic Developments
- Lifeward Transaction (Subsequent Event): On March 25, 2026, Oramed closed a transaction transferring its POD (Protein Oral Delivery) technology and OraTech subsidiary to Lifeward Ltd. In exchange, Oramed received approximately 49.99% of Lifeward's fully diluted equity, warrants, and a 4% revenue share on Lifeward's ReWalk products. Future R&D costs for oral insulin will be borne by OraTech/Lifeward.
- Oral Insulin Clinical Trial: Oramed plans to initiate a 60-patient, US-based Phase 3 clinical trial in the second half of 2026 to validate oral insulin efficacy in specific high-responder subpopulations identified from previous data.
- Scilex Exposure: Oramed holds significant secured notes (Tranche A and B) and warrants in Scilex Holding Company. While Scilex has made repayments, the company notes substantial doubt regarding Scilex's ability to continue as a going concern, posing a risk to the recovery of the remaining principal.
- Real Estate Strategy: The Board approved up to $30 million in real estate investments, including loans for projects in Israel (Rabi Binyamin, Hapisga) and land acquisition, aiming for long-term value appreciation and income streams.
- Dividend: A special cash dividend of $0.25 per share was declared on December 31, 2025, and paid in January 2026.
Investor Verification Checklist
- Quality of Earnings: Verify the sustainability of the $64M net income, which is derived from fair value adjustments of investments (Alpha Tau, Scilex) rather than product sales. These gains are non-cash and volatile.
- Scilex Credit Risk: Assess the recoverability of the remaining ~$19.7M principal balance on Scilex notes (Tranche A and B) given Scilex's disclosed "substantial doubt" about its going concern status.
- Lifeward Transaction Terms: Review the final terms of the Lifeward Share Purchase Agreement, specifically the valuation of the equity received and the conditions for the additional $9M note purchase.
- Cash Runway: Confirm the company's ability to fund operations and the new 60-patient clinical trial without additional financing, given the reduction in cash and cash equivalents to ~$46M.
- Regulatory Path: Monitor the FDA's response to the revised Phase 3 protocol for oral insulin, as the previous Phase 3 trial failed to meet primary endpoints.